Breast cancer (BC) is the most common malignancy in women. Most of the tumors are detected at early stages and treated with curative intent. However, up to one third of patients relapse, of which 70% develop bone metastases with survival rates dropping under 10% at 5 years. Efforts to find markers of bone metastases development have so far failed, mainly due to the poor understanding of early pathogenetic steps. Therefore, there remains a need for biomarkers that identify patients at high risk for bone metastases. In addition, despite the frequency of skeletal involvement and the associated morbidity and mortality, effective strategies to prevent bone metastases are lacking.
Datum
|
1. 12. 2019 - 30. 11. 2022 |
Länderkürzel
|
AT |
Name der begünstigten Einrichtung
|
Karl Landsteiner Privatuniversität für Gesundheitswissenschaften GmbH |
Projektleitung
|
wissenschaftliche Arbeitsgruppen›Molekulare Hämatologie / Onkologie); Sonia Vallet (KL>Universitätsklinik für Innere Medizin›Klinische Abteilung für Innere Medizin 2 (UK Krems) |
Verknüpfung
|
www.kl.ac.at |
Förderrahmen & Förderprogramm
|
Gesellschaft für Forschungsförderung Niederösterreich, Life Science Call 2018 |
